Drugs & Targets FDA approves updated drug labeling for Xeloda tablets under Project Renewal December 16, 2022Vol.48 No.45
Drugs & Targets Tecentriq receives FDA approval for alveolar soft part sarcoma December 16, 2022Vol.48 No.45
Drugs & Targets Krazati receives FDA accelerated approval for KRAS G12C-mutated NSCLC December 16, 2022Vol.48 No.45
Conversation with The Cancer Letter FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials December 09, 2022Vol.48 No.44By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
In Brief Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers December 02, 2022Vol.48 No.43
Drugs & Targets FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation December 02, 2022Vol.48 No.43
Drugs & Targets Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer December 02, 2022Vol.48 No.43
